@article {Blout Zawatsky2021.08.03.21261489, author = {Carrie L. Blout Zawatsky and Nidhi Shah and Kalotina Machini and Emma Perez and Kurt D. Christensen and Hana Zouk and Marcie Steeves and Christopher Koch and Melissa Uveges and Janelle Shea and Nina Gold and Joel Krier and Natalie Boutin and Lisa Mahanta and Heidi L. Rehm and Scott T. Weiss and Elizabeth W. Karlson and Jordan W. Smoller and Matthew S. Lebo and Robert C. Green}, title = {Returning Actionable Genomic Results in a Research Biobank: Analytic Validity, Clinical Implementation and Resource Utilization}, elocation-id = {2021.08.03.21261489}, year = {2021}, doi = {10.1101/2021.08.03.21261489}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Over 100 million research participants around the world have had research array-based genotyping (GT) or sequencing (GS), but only a small fraction of these have been offered return of actionable genomic findings (gRoR). Between 2017 and 2021, we analyzed genomic results from 36,417 participants in the Mass General Brigham Biobank and offered to confirm and return pathogenic and likely pathogenic variants (PLPVs) in 59 genes. Variant verification prior to patient recontact revealed that GT falsely identified PLPVs in 44.9\% of samples, and GT failed to identify 72.0\% of PLPVs detected in a subset of samples that were also sequenced. GT and GS detected verified PLPVs in 1\% and 2.5\% of the cohort, respectively. Of 256 participants who were alerted that they carried actionable PLPVs, 37.5\% actively or passively declined further disclosure. 76.3\% of those carrying PLPVs were unaware that they were carrying the variant and over half of those met published professional criteria for genetic testing but had never been tested. This gRoR protocol cost approximately $129,000 USD per year in laboratory testing and research staff support, representing $14 per participant whose DNA was analyzed or $3,224 per participant in whom a PLPV was confirmed and disclosed. These data provide logistical details around gRoR that could help other investigators planning to return genomic results.Competing Interest StatementDr. Weiss has received compensation from UpToDate. Dr. Smoller is a member of the Leon Levy Foundation Neuroscience Advisory Board and received an honorarium for an internal seminar at Biogen, Inc. He is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. Dr. Green has received compensation for advising the following companies: AIA, Genomic Life, Grail, Humanity, Kneed Media, Plumcare, OptumLabs, Verily, VibrentHealth; and is co-founder of Genome Medical. Funding StatementThis work was primarily funded by NIH grant HG008685, with additional support from NIH grants HG008676, HG009173, HD090019, HG008676, HG009922, HL143295, OD026553, TR003201 and the Franca Sozzani Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham IRB protocols: 2009P002312 and 2015P000983All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-level MGBB data are available from: https://personalizedmedicine.partners.org/Biobank/Default.aspx, however, there are restrictions on this data which was accessed under IRB protocol 2009P002312 for this current study so are not publicly available. Samples sequenced or genotyped as part of the eMERGE consortium are deposited in dbGAP https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001616.v1.p1 and https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001584.v2.p2. https://personalizedmedicine.partners.org/Biobank/Default.aspx https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001616.v1.p1 https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001584.v2.p2}, URL = {https://www.medrxiv.org/content/early/2021/08/05/2021.08.03.21261489}, eprint = {https://www.medrxiv.org/content/early/2021/08/05/2021.08.03.21261489.full.pdf}, journal = {medRxiv} }